Processing Magazine

J&J knowingly sold defective insulin pumps, FDA says

January 11, 2012

WASHINGTON — The Food and Drug Administration has accused Johnson & Johnson’s Animas unit of continuing to sell insulin pumps last year after learning of defects with the devices, Bloomberg reported.

According to the FDA letter, which was dated Dec. 27 and released today, the J&J unit continued to manufacture insulin pumps after they “had known failures.”

The issues with Animas’ OneTouch Ping and 2020 pumps prompted a company investigation that started in April, the article stated.